Collaboration with Fraunhofer SCAI
APTA Therapeutics is pleased to announce that it has entered into a collaboration with the Fraunhofer Institute for Algorithms and Scientific Computing (SCAI) to implement state-of-the-art data-and knowledge-driven methods to better define patient recruitment for the upcoming clinical trials in post-viral infectious diseases.
APTA Therapeutics CEO Dr. Oliver von Stein interviewed by Tagesspiegel
Click here for the article:
(Full article requires a subscription)
Dr. Oliver von Stein, CEO of APTA Therapeutics, featured in RiffReporter
Click here for the article:
https://www.riffreporter.de/de/wissen/long-covid-mecfs-bc007-rovunaptabin-klinische-studien-erlangen-apta-berlin-cures
(Full article requires a subscription)
APTA Therapeutics Receives Notice of Allowance for Key Patent in the United States and Japan
APTA Therapeutics, today announced that it has received notices of allowance for a key patent application in both the United States and Japan, marking a significant milestone in the company’s intellectual property strategy.
Agreement with CIBIT
APTA Therapeutics is pleased to announce that it has entered into an agreement with Coimbra Institute for Biomedical Imaging and Translational Research (CIBIT) to support an Investigator Initiated Trial with rovunaptabin in patients with long COVID.
APTA Therapeutics welcomes Dr. Daniel Bock as Chief Scientific Officer / Chief Operational Officer
APTA Therapeutics, a clinical-stage biopharmaceutical company focused on developing innovative therapies for diseases associated with regulatory autoantibodies, strengthens its management team.
Interview with CEO Dr. Oliver von Stein in “The Sick Times”
Click here for the article:
APTA Therapeutics acquires all assets from Berlin Cures
The newly founded APTA Therapeutics has acquired assets from Berlin Cures and intends to continue clinical development of rovunaptabin, formally BC 007.